In recent years, China's pharmaceutical regulatory system has undergone major changes, with the aim of achieving the effects of management jump, concept renewal and technological progress, which has led to close study and exchange between the Chinese pharmaceutical industry and the foreign pharmaceutical industry.

Domestically, the biggest impact on the API industry is environmental protection. With the implementation of various new environmental protection policies such as water quotas, emission standards, pollutant discharge permits, environmental protection taxes, etc., the number of API companies due to environmental rectification, relocation, shutdown and suspension of production is increasing, and enterprises are required to meet relevant environmental protection. Standards and requirements, investing a large amount of money to add and upgrade environmentally friendly equipment, equipped with relevant personnel and technology. This has eliminated many of the backward production capacity, and at the same time, the production cost of the raw material drug manufacturers has risen linearly. The direct result is the instability of the supply chain, causing many problems for many domestic manufacturers.

        Shanghai Mingren Medicine is a company with rich resources and experience in pharmaceutical import trade. Its main members have decades of experience in management, production, marketing and sales of multinational pharmaceutical companies, thus establishing a good and perfect business network. The Mingren team has also introduced dozens of preparations and APIs to China in the past 20 years, and has established a good reputation in the industry. Our services include finding quality European suppliers, assisting in the registration of imported APIs, and sales of domestic APIs. In the future, Mingren will uphold the company's consistent creed, bring convenience to domestic pharmaceutical companies, and contribute to the improvement of China's pharmaceutical reform quality.